Abstract
Intraperitoneal chemotherapy poses both potential benefits as a cancer treatment and negative consequences on patient and family quality of life. The profound multi-dimensional quality of life impact of intraperitoneal (IP) chemotherapy upon women with advanced ovarian cancer makes the early integration of palliative care particularly important for this population. Numerous opportunities occur throughout the treatment process to improve the delivery of biopsychosocial-spiritual support to women receiving IP chemotherapy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
California
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Female
-
Humans
-
Infusions, Parenteral
-
Middle Aged
-
Narration
-
Ovarian Neoplasms / complications
-
Ovarian Neoplasms / drug therapy
-
Ovarian Neoplasms / psychology
-
Ovarian Neoplasms / therapy*
-
Paclitaxel / administration & dosage
-
Paclitaxel / adverse effects
-
Palliative Care*
-
Qualitative Research
-
Quality of Life*
-
Retrospective Studies